12:40 , Aug 12, 2019 |  BioCentury  |  Finance

Chipscreen sets high standard in Shanghai debut

Chipscreen became the first biopharma to begin trading on Shanghai’s STAR market this week, and the strength of its debut could entice companies sitting on the sidelines to choose a mainland listing over one in...
00:37 , Jul 31, 2019 |  BC Extra  |  Financial News

Chipscreen sets pace for biotech IPOs in Shanghai

Chipscreen became the first biopharma to price its IPO on Shanghai’s STAR market Tuesday, raising RMB1 billion ($148.2 million) in an upsized offering that signals that the investor exuberance that drove big gains for the...
21:42 , Jul 3, 2019 |  BC Extra  |  Financial News

July 3 Financial Quick Takes: Mega-round for China’s Lepu; plus Citryll, Jibeier and Calliditas

Shiyu Capital leads Lepu’s $131M A round  Lepu Biotechnology Co. Ltd. closed a RMB900 million ($130.7 million) series A round led by Shiyu Capital. Sumin Investment, Kaiyuan Guochuang, Suzhou Xinrui, Le Cheng Medical, and existing...
22:49 , Jun 7, 2019 |  BC Extra  |  Financial News

Chipscreen set to test Shanghai’s new innovation board

Chipscreen could soon become the first biotech to list on the Shanghai Stock Exchange’s new science and technology innovation board after its application was approved this week. The application from Shenzhen Chipscreen Biosciences Ltd. (Shenzhen,...
17:29 , Jan 11, 2019 |  BC Week In Review  |  Financial News

Suzhou-based BrightGene raises pre-IPO round

BrightGene Bio-Medical Technology Co. Ltd. (Suzhou, China) raised RMB550 million ($80.3 million) in a venture round on Jan. 7. The company described the funding as a "pre-IPO round," but did not immediately respond to an...
20:23 , Jan 7, 2019 |  BC Extra  |  Financial News

Suzhou-based BrightGene raises pre-IPO round

BrightGene Bio-Medical Technology Co. Ltd. (Suzhou, China) raised RMB550 million ($80.3 million) in a venture round. The company described the funding as a "pre-IPO round," but did not immediately respond to an inquiry about its...